5313492026-01-012026-03-315313492026-03-315313492025-03-315313492025-04-012026-03-315313492026-01-012026-03-31in-capmkt:OtherExpenses1Member5313492025-04-012026-03-31in-capmkt:OtherExpenses1Member5313492026-03-31OtherNoncurrentFinancialAssetsDomain15313492026-03-31OtherNoncurrentFinancialAssetsDomain25313492026-03-31OtherNoncurrentAssetsDomain15313492026-03-31OtherCurrentFinancialAssetsDomain15313492026-03-31OtherCurrentAssetsDomain15313492026-03-31OtherNoncurrentFinancialLiabilitiesDomain15313492026-03-31OtherNoncurrentLiabilitiesDomain15313492026-03-31OtherCurrentFinancialLiabilitiesDomain15313492026-03-31OtherCurrentLiabilitiesDomain15313492026-01-012026-03-31in-capmkt:ReportableSegments1Member5313492026-01-012026-03-31in-capmkt:ReportableSegments2Member5313492025-04-012026-03-31in-capmkt:ReportableSegments1Member5313492025-04-012026-03-31in-capmkt:ReportableSegments2Member5313492026-01-012026-03-31in-capmkt:ReportableSegments1Member5313492026-01-012026-03-31in-capmkt:ReportableSegments2Member5313492025-04-012026-03-31in-capmkt:ReportableSegments1Member5313492025-04-012026-03-31in-capmkt:ReportableSegments2Member5313492026-01-012026-03-31in-capmkt:ReportableSegments1Member5313492026-03-31in-capmkt:ReportableSegments1Member5313492026-01-012026-03-31in-capmkt:ReportableSegments2Member5313492026-03-31in-capmkt:ReportableSegments2Member5313492026-01-012026-03-31in-capmkt:ReportableSegments1Member5313492026-03-31in-capmkt:ReportableSegments1Member5313492026-01-012026-03-31in-capmkt:ReportableSegments2Member5313492026-03-31in-capmkt:ReportableSegments2Member5313492026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15313492025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15313492026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15313492025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15313492026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares531349PANACEABIONOTLISTEDINE922B01023Panacea Biotec LimitedMain BoardEquity2025-04-012026-03-312026-05-302026-05-26INRLakhsQuarterlyFourth quarterMulti segment2026-05-3016:30:002026-05-3020:10:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated166750000025500000169300000080780000026700000-7060000046820000012000000788000004097000001732600000-3960000027100000-125000003500000-6000000-25000000-100000000000-1000000049900000399000005200000-1520000055100000-152000006130000010.080.08000.080.08Notes: <BR> 1. The financial results for the quarter and year ended March 31, 2026 were reviewed by the Audit Committee at its meeting held on May 29, 2026 and approved by the Board of Directors of the Company at its meeting held on May 30, 2026, and have been audited by the statutory auditors of the Company. <BR> 2. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (“Ind AS”) notified under the Companies (Indian Accounting Standards) Rule, 2015, as amended from time to time, specified under section 133 of the Companies Act, 2013. <BR> 3. The consolidated financial results of the Company have been prepared by consolidating the Company's audited financial results of the Company and its material subsidiary for the respective periods, with the audited / unaudited (management reviewed and approved) financial results of other wholly owned subsidiaries (“WOS”) and the Enterprises over which the Company exercises control (the Company, these subsidiaries and the Enterprises hereinafter collectively referred to as “the Group”) are as follows: <BR> (i) Audited - Indian WOS: Panacea Biotec Pharma Limited (“PBPL”) & Meyten Realtech Private Limited; Overseas WOS: Panacea Biotec Inc. (WOS through PBPL); and Enterprises over which the Company exercises control*: PanEra Biotec Private Limited & Adveta Power Private Limited; and <BR> (ii) Unaudited - Overseas WOS: Panacea Biotec (International) S.A. (“PBS”) and Panacea Biotec Germany GmbH (WOS through PBS). <BR> *considered as a subsidiary for the purpose of consolidation as per Ind AS 110 <BR> 4. For the financial year ended March 31, 2026, the Company and Group has incurred loss (including other comprehensive income) of Rs.2,874 Lakh and Rs.174 Lakh (year ended March 31, 2025: loss of Rs.1,518 Lakh and Rs.761 Lakh), respectively and as on March 31, 2026, the retained earnings of the Company are negative to the extent of Rs.21,782 Lakh (March 31, 2025: Rs.18,909 Lakh). The aforesaid conditions indicate the existence of uncertainty that may create doubt about the Company's ability to continue as a going concern. However, the retained earnings of the Group are positive to the extent of Rs.77,605 Lakh (March 31, 2025: Rs.77,991 Lakh). The surplus funds remaining with the Group out of the sales of pharmaceutical formulations brands in India and Nepal in March 2022 have helped in strengthening the working capital position, setting up new facilities for enhancement of capacities for manufacturing of vaccines drug substance, scaling up its nutrition and pharmaceutical formulations business and pursuing other business opportunities. The Company has already received higher long-term business orders for vaccines from key institutional customers. Based on these measures and continuous efforts to improve the business performance, the management has prepared the financial results on a going concern basis. <BR> 5. During the financial year ended March 31, 2026, the Group has recognised exception income of Rs.1,950 Lakh (year ended March 31, 2025: Rs.3,599 Lakh) in the consolidated statement of profit and loss, which includes: <BR> (i) revenue of Rs.857 Lakh (year ended March 31, 2025: Nil), pursuant to the settlement agreement dated July 9, 2025 executed with Apotex Inc., USA (“Apotex”) to settle the ongoing dispute between Apotex and the Company & PBPL; and <BR> (ii) revenue of Rs.1,092 Lakh (year ended March 31, 2025: Rs.3,599 Lakh), out of the remaining deferred consideration of Rs.2,111 Lakh as at March 31, 2025, from sale of domestic pharmaceutical brands of PBPL. The balance deferred consideration of Rs.1,019 Lakh (March 31, 2025: Rs.2,111 Lakh) would be recognised in subsequent quarters / years and is shown as Contract Liability in the consolidated financial statements of the Group. <BR> 2025-04-012026-03-31AuditedConsolidated63977000001690000006566700000290240000089700000-18730000018078000006050000033060000018317000006835400000-268700000195000000-737000004300000-6400000-21000000-716000000000-7160000054200000-17400000-53700000-17900000500000-179000006130000018287100000-0.88-0.8800-0.88-0.88Other Expenses409700000Other Expenses18317000005532700000999700000155000000067700000441200000007000000028210000028280000012200000749130000019279000001003000007352000005731000007060000019400000602600000210120000011013000005130400000126217000006130000082871000008348400000-59600000828880000023660000000046000002412000003662000002314000007300000846100000022210000016739000001896000000100400000199640000010753000003948000002030000034868000004332900000126217000006. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (‘Labour Codes') which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes including a uniform definition of wages. The incremental impact of these changes, assessed by the Company / Group, on the basis of the information available, consistent with the guidance provided by the Institute of Chartered Accountants of India, has been accounted for accordingly. Once Central / State Rules are notified by the Government on all the aspects of the Labour Codes, the Company / Group will evaluate additional impact, if any, on the measurement of employee benefits and would provide appropriate accounting effect. <BR> 7. The standalone and consolidated financial results for the year ended March 31, 2026 and March 31, 2025, include deferred tax (benefit) / charge of (Rs.153 Lakh) and Rs.36 Lakh {March 31, 2025: (Rs.416 Lakh) and Rs.270 Lakh}, respectively on account of adjustments pertaining to earlier years. <BR> 8. During the quarter ended March 31, 2026, the enrollment of study participants in context of DengiAll® Phase-III clinical trial has been completed. DengiAll® will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027 after successful completion of the clinical trial and receipt of necessary regulatory approvals. <BR> 9. Amounts for the quarter ended March 31, 2026 and March 31, 2025 represent the balancing amounts between the audited amounts for the full financial year and the published year to date amounts upto third quarter of the respective financial years, which had been subjected only to limited review. <BR> 10. The Company publishes standalone financial results along with the consolidated financial results. In accordance with Ind AS 108, ‘Operating Segments’, the management has disclosed the segment information in the consolidated financial results. Accordingly, the segment information is given in the consolidated financial results of the Group for the quarter and year ended March 31, 2026. <BR> 11. The necessary certificate / report in respect of the above results in terms of requirements of Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015, has been placed before the Board of Directors. <BR> 12. Previous period amounts have been regrouped/ reclassified in compliance with Ind-AS to make them comparable with those of current period / year. <BR> 13. ‘0’ under “Rs. in Lakh” represents an amount less than Rs.50,000. Further, the figures shown in the tables may not exactly add up due to rounding off. <BR> 14. The above results are also available on the Company’s website https://www.panaceabiotec.com. <BR> Income Tax Asset162500000Other financial Assets119600000Other non current asset12200000Other Financial Assets602600000Other current assets1101300000Other financial liabilities4600000Other non-current liabilities7300000Other financial liabilities100400000Other current liabilities1075300000Vaccines1079500000Formulations588000000Vaccines4102500000Formulations2295200000166750000063977000000016675000006397700000Vaccines-34500000Formulations22000000Vaccines-268400000Formulations194700000-12500000-737000000000-12500000-73700000Vaccines8701400000Formulations392030000012621700000012621700000Vaccines3020200000Formulations131270000043329000000433290000060500000208800000128000000328800000-340000000143000001041000000-4238000000315400000-10120000033060000003120000033000000-4380000005330000004160000000000-12600000052980000045610000000064500000-22480000016680000000000000054090000000000000000000000041600000094400000-40490000000000000337000000004420000000-10500000-248600000400000-248200000821300000573100000Items that will not be reclassified to profit or loss1460000014600000Items that will not be reclassified to profit or loss203000002030000037000005100000Items that will be reclassified to profit or loss3900000039000000Items that will be reclassified to profit or loss3900000039000000004990000054200000AuditedtrueSuresh Surana & Associates LLPtrue2028-03-31